Glenmark Pharmaceuticals

GLENMARK.NSApproved

Glenmark Pharmaceuticals Limited is a research-driven global pharmaceutical company founded in 1977 and headquartered in Mumbai, India. The company operates across the pharmaceutical value chain with significant investments in R&D, particularly in respiratory diseases, dermatology, and oncology. Glenmark has successfully developed and commercialized innovative drugs while building a strong generic pharmaceuticals portfolio across key markets including the US, Europe, and emerging markets.

Market Cap

$6.6B

Employees

10,000-15,000

Focus

Biotech

GLENMARK.NS · Stock Price

USD 2180.00+1744.45 (+400.52%)

Historical price data

AI Company Overview

Technology Platform

Integrated pharmaceutical platform encompassing generic formulations, API manufacturing, innovative drug discovery, and biosimilar development with focus on complex molecules and specialty therapeutics.

Pipeline Snapshot

25 drugs in pipeline, 9 in Phase 3

Drug	Indication	Stage
Diclofenac Sodium gel, 1% + Voltaren® Gel + Placebo	Osteoarthritis	Phase 3
Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel + BenzaClin® Topical Gel, Clindam...	Acne Vulgaris	Phase 3
Nitric Oxide	SARS-CoV-2 Infection	Phase 3
Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching...	Bronchial Asthma	Phase 3
Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064% + Enstilar...	Psoriasis Vulgaris	Phase 3

Funding History

IPOUndisclosedUndisclosedJun 15, 1999

FDA Approved Drugs

181

FLUTICASONE PROPIONATEANDAMar 16, 2026

POTASSIUM PHOSPHATESANDAMar 12, 2026

FLUTICASONE PROPIONATEANDAMar 3, 2026

Opportunities

Glenmark has significant growth opportunities through its innovative pipeline in respiratory and dermatology, expanding biosimilar portfolio, and continued geographic expansion in emerging markets.

The company's strong R&D capabilities and integrated manufacturing platform position it well for capturing market share in specialty therapeutics.

Risk Factors

Key risks include intense competition in generic pharmaceuticals leading to pricing pressure, regulatory compliance challenges particularly with FDA inspections, and currency fluctuation impacts due to global operations.

Patent litigation and exclusivity losses also pose ongoing challenges to revenue streams.

Competitive Landscape

Glenmark competes in a highly fragmented pharmaceutical market against both Indian companies like Sun Pharma, Cipla, and Dr. Reddy's, as well as global generics players like Teva and Sandoz. The company differentiates itself through its focus on specialty therapeutics, integrated API-formulation capabilities, and strong presence in emerging markets.

Publications

Pipeline

FDA Approvals

181